Biodesix Reports 41% Surge in Q4 Revenue, Exceeds Full-Year Guidance with Strong Lung Diagnostics Growth
Fourth Quarter Revenue Jumps 41% as Lung Diagnostics Outpaces Expectations
Biodesix (NASDAQ:BDSX) delivered impressive preliminary financial results for the fourth quarter and full year of 2025. The company estimates Q4 revenue rose 41% year-over-year to $28.8 million, while full-year revenue reached $88.5 million—beating the upper end of its own $84 to $86 million guidance range. Fueled by robust growth in its Lung Diagnostics segment and expanding test volumes, Biodesix showcased clear operational momentum despite tough competition in the diagnostics space.
Growth Driven by Lung Diagnostics and Volume Expansion
The standout performer in Biodesix's portfolio was its Lung Diagnostics segment. Estimated revenue from Lung Diagnostics came in at $25.2 million for Q4 (up 47% vs. last year) and $79.2 million for the year (up 22%). Notably, fourth quarter test volumes increased 23% year-over-year to 18,000, representing a strong pipeline of physician and patient demand. These gains were supported by increased reimbursement and average revenue per test, as well as approximately $1 million recognized from older claims that had previously lingered on the books.
| Segment | Q4 2025 Revenue ($M) | Full-Year 2025 Revenue ($M) | Q4 YoY Change | Full-Year YoY Change | Q4 Test Volume | Full-Year Test Volume |
|---|---|---|---|---|---|---|
| Lung Diagnostics | 25.2 | 79.2 | +47% | +22% | 18,000 | 62,600 |
| Development Services | 3.6 | 9.3 | +13% | +41% | - | - |
Growth Across All Segments: Development Services also contributed to the overall momentum, with Q4 revenue growing 13% year-over-year to $3.6 million and full-year revenue climbing 41% to $9.3 million. Combined, these results reflect both a strengthening core business and successful execution in expanding high-margin service partnerships.
Guidance Affirmed: Adjusted EBITDA Turning Positive
Biodesix affirmed its guidance for positive Adjusted EBITDA in the fourth quarter, marking an important milestone for a company in growth mode. Executives credited "accelerating growth in Lung Diagnostics testing revenue, driven by an increase in test volumes and continued expansion of reimbursement," along with "operating leverage" throughout the year.
Cash and cash equivalents stood at $19.0 million at the end of 2025, registering a 14% increase from the third quarter—even when excluding $2.3 million in at-the-market proceeds, the cash balance grew $0.1 million to $16.7 million. The company’s CEO, Scott Hutton, highlighted the team’s "unwavering commitment to healthcare professionals and patients" as a key factor behind this operational success.
Takeaway: Momentum Sets the Stage for 2026
With revenue outpacing guidance and strong signals from both its Lung Diagnostics and Development Services businesses, Biodesix enters 2026 on solid footing. Investors and healthcare stakeholders alike will want to monitor how continued growth in test volumes and successful reimbursement strategies play out in the company’s audited results and future strategic moves. As the diagnostics space remains competitive, Biodesix’s performance so far hints at ongoing growth opportunities in the year ahead.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI